Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Freshworks Inc (FRSH) vs Smith & Nephew plc (SNN) Price & Performance

Freshworks IncTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Freshworks Inc vs Smith & Nephew plc — how do they compare? Freshworks Inc trades at $11.97 (market cap $3.31B), while Smith & Nephew plc trades at $30.23 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 3.8× Freshworks Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.

FRSHSNN
Market Cap
$3.31B$12.54B
Sector
TechnologyHealth
52-Week High
$13.97$38.70
52-Week Low
$6.88$28.73
Enterprise Value
$2.68B$15.57B
Dividend Yield
2.65%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Freshworks Inc

Freshworks (FRSH) trades at $11.67, down 2.59% on the day, with a bullish technical signal from moving averages but a neutral RSI. The company reported strong Q2 2026 results, beating earnings estimates with $0.17 EPS, and achieved its first quarter of GAAP profitability in 2026. Revenue growth remains robust at 16% year-over-year, supported by strength in its employee experience (EX) segment, which now represents 60% of ARR.

The outlook is positive, with a consensus price target of $16.50 implying significant upside. Key opportunities include AI monetization and public sector expansion via FedRAMP progress. Risks include high valuation multiples like a 40.22 EV/EBITDA and competitive pressure in the SaaS sector. Analyst sentiment is evenly split between Buy and Hold ratings.

Smith & Nephew plc

SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.

The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.

Returns comparison

Trailing returns across standard periods

About Freshworks Inc

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.

Read more on FRSH

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN